🔗 Share this article

An underground market for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Drug Acquiring Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are encouraged to message these profiles privately for supplier links, while also obtaining discount codes.

Active Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where communities with thousands of members share “before and after” images, administration instructions and assertions of rapid UK delivery. Sellers promote the substance there before redirecting buyers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Professionals Express Worries

However, physicians and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users injecting substances of unknown origin.

Several professionals stated the demand for retatrutide could be linked to the increasing price of approved weight loss products such as Mounjaro.

Regulatory Status and Implementation

Marketing retatrutide on TikTok or Telegram is illegal in the UK, as it is an unlicensed medication that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach medicines, advertising, and consumer regulations, potentially leading to fines, prosecution or imprisonment.

Platform Response and Material Elimination

Based on the social media company, the service has removed problematic material and banned related keywords and search suggestions. The company said it was committed to maintaining the platform secure and investing in strengthening enforcement strategies.

Digital Trading Activities

Research also found groups with up to nine thousand participants selling retatrutide using Telegram's built-in search feature, which functions like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with photos of slimming results, positive reviews and step-by-step guides for preparing or administering at residence.

After minutes of joining one community, a seller shared contact information, where the majority of purchases take place. The seller provided an instruction manual and promised shipping within two days. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one asked about body mass, health issues or previous experience.

Item Details and Costs

Inside these groups, posts show dark colored packages with postal service labels, stating to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at residence with purified liquid, or pre-filled injectors usually sold at £160 for 20 milligrams. When questioned how long a injector should last, sellers give contradictory responses ranging from a several days to “depends on your body”.

Platform Oversight and Security Measures

A spokesperson for Telegram stated it regularly moderated dangerous content on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are administering materials they cannot confirm. Although the research behind this drug is sound, these digital versions may not contain what they advertise,” stated a pharmacy expert, the director of pharmacy at Chemist4U.

A medical professional of Asda Online Doctor linked the surge in demand to current cost increases for approved weight-loss drugs such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s contained or whether the conditions they were produced in was clean,” she explained.

Her team has previously encountered patients harmed by self-injection from unverified sources. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These substances could be contaminated or improperly measured.”

Producer Statement

A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a Lilly experimental product not yet authorized … may expose patients to possibly serious medical dangers”.